Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis.
about
Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitisOptimization of the treatment with immunosuppressants and biologics in inflammatory bowel diseaseTacrolimus for the Treatment of Ulcerative ColitisReview article: acute severe ulcerative colitis - evidence-based consensus statements.Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitisThe earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patientsMucosal healing in inflammatory bowel disease-a true paradigm of success?Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS.Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis.Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus.The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic ScoreOral tacrolimus as maintenance therapy for refractory ulcerative colitis--an analysis of outcomes in two London tertiary centres.Ulcerative colitis: prevention of relapse.Review article: strategies for the management of chronic unremitting ulcerative colitis.Pediatric ulcerative colitis: a practical guide to management.Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis.Treatment of IBD: where we are and where we are going.Conventional drug therapy for inflammatory bowel disease.Management of severe ulcerative colitis.Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It?Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks?Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis.Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease.Optimizing pharmacologic management of inflammatory bowel disease.Evaluating Study Withdrawal Among Biologics and Immunomodulators in Treating Ulcerative Colitis: A Meta-analysis of Controlled Clinical Trials.A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis.Recent trends and future directions for the medical treatment of ulcerative colitis.Acute severe ulcerative colitis: from pathophysiology to clinical management.Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study.Two Cases of Severe Ulcerative Colitis with Colonic Dilatation Resolved with Tacrolimus Therapy.Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study.Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?Commentary: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis.Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era.Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients.The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients.Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients.
P2860
Q26798299-60F66C8C-A229-4BFE-8F03-D930EB388D65Q26823221-C3E69BD6-FB33-4481-BC18-09C29B73DA3BQ26866940-859CD9C0-14A9-4707-BF83-43F719A67714Q26997361-FFE84DF8-F9A8-477C-BFE4-F8CF005C099BQ34528270-F4CC38C7-2692-4EE6-A02A-381309FF99AEQ35069498-BEA6F470-C412-4D2E-8A74-76F790F22500Q35618156-65D55C10-9FEC-46F1-83A4-D46B011ED744Q35749943-A395AA7A-830D-4491-B01F-6E6A832A6165Q35889006-6C10311B-2A29-435B-9CB0-1F64BEDB7718Q36317757-3B0234FE-8E15-419B-8A0F-66460C4A3519Q36793729-F36FEAAF-702B-4026-8E70-17E88BEB7FB9Q36830507-97385038-C33E-473F-ABAB-B948F810FBABQ37118462-C939C454-B16F-4EE5-B476-703413F4C7D3Q38102458-C19AC811-E49D-48FE-B4A4-F1EF6234BBABQ38103628-C3EC241D-B02F-4F48-AA36-AC36E0244078Q38110317-586A9695-A06A-4DE6-BBF5-FF6438F972E5Q38203832-44C8A482-3865-411D-8F9F-C0004A607833Q38204993-900C258B-ADB3-479C-8D49-63DD81235155Q38285619-A1EFE24E-1B66-4810-A983-8B1CEEA36DABQ38293796-2F751857-D314-40C8-9A44-9C2CB5BD0794Q38321528-AF8EAFA0-F390-4D6B-B5DC-9DC08F7C747DQ38331566-038C9056-984D-4ACF-8418-C190659BE430Q38404037-DD3A2F35-44B7-409A-98AA-B31D1458B83DQ38662186-D1BFA47C-6320-4B29-B023-ACF08E71B1D1Q38671272-804018B1-2CD6-43C2-9F66-BE363C453A0AQ38687407-097AE871-15D7-4C03-8B9F-261B31077DDFQ38714318-C5C8294D-F8EC-418B-B00A-EB3E40B912A8Q38734964-3C102CBB-3B3E-4A33-BAE0-71A2F1E11D28Q38815035-DE8D4EF3-7E22-4754-855E-8B9FD3DC42B3Q38942561-14D5E860-35EF-423D-B6A4-61B2A3124741Q39098635-B3180467-D567-4FBD-AEE9-145B55EB0383Q40104067-B1AA5DD0-981A-4277-A282-9D7617FC2A90Q40140168-D553C2EA-5805-440F-A11E-2C493C333D33Q42648367-4393E6CE-2B4D-4DF3-96C7-C4614D91CBABQ42695266-6CE04D47-E8FC-44F9-BAA6-949D911FE519Q43486158-7809E965-0199-40AE-867A-FA4FB0443752Q43497300-081BEEF4-712E-47C0-A0C5-8311D987B55FQ43611596-000927D6-178A-40F1-93F4-BCE3D891DF88Q44033640-FF7D38B8-339A-4E40-B3D7-0FA7FC6F7D81Q45831311-6FA0BBFA-69F6-4DA1-9B50-9EF87363C307
P2860
Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Double-blind, placebo-controll ...... refractory ulcerative colitis.
@ast
Double-blind, placebo-controll ...... refractory ulcerative colitis.
@en
Double-blind, placebo-controll ...... refractory ulcerative colitis.
@nl
type
label
Double-blind, placebo-controll ...... refractory ulcerative colitis.
@ast
Double-blind, placebo-controll ...... refractory ulcerative colitis.
@en
Double-blind, placebo-controll ...... refractory ulcerative colitis.
@nl
prefLabel
Double-blind, placebo-controll ...... refractory ulcerative colitis.
@ast
Double-blind, placebo-controll ...... refractory ulcerative colitis.
@en
Double-blind, placebo-controll ...... refractory ulcerative colitis.
@nl
P2093
P2860
P921
P356
P1476
Double-blind, placebo-controll ...... refractory ulcerative colitis.
@en
P2093
Fumihito Hirai
Haruhiko Ogata
Katsuyoshi Koyanagi
Nobuyuki Hida
Takayuki Matsumoto
Toshifumi Hibi
Toshiyuki Matsui
P2860
P304
P356
10.1002/IBD.21853
P577
2011-09-01T00:00:00Z